Discontinued — last reported Q3 '25
Omnicom Group Equity Method Investments decreased by 11.1% to $58.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 4.2%, from $61.20M to $58.60M. Over 5 years (FY 2020 to FY 2025), Equity Method Investments shows a downward trend with a -5.0% CAGR.
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
These are investments in entities where the company exercises significant influence but does not have full control. The...
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
equity_method_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $79.10M | $77.80M | $76.30M | $77.60M | $69.60M | $64.20M | $66.20M | $66.40M | $67.10M | $65.40M | $66.40M | $64.80M | $63.30M | $65.80M | $59.00M | $61.20M | $60.20M | $66.20M | $65.90M | $58.60M |
| QoQ Change | — | -1.6% | -1.9% | +1.7% | -10.3% | -7.8% | +3.1% | +0.3% | +1.1% | -2.5% | +1.5% | -2.4% | -2.3% | +3.9% | -10.3% | +3.7% | -1.6% | +10.0% | -0.5% | -11.1% |
| YoY Change | — | — | — | — | -12.0% | -17.5% | -13.2% | -14.4% | -3.6% | +1.9% | +0.3% | -2.4% | -5.7% | +0.6% | -11.1% | -5.6% | -4.9% | +0.6% | +11.7% | -4.2% |